Global Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease (AMD, Diabetic Retinopathy), by Product (Beovu, Eylea) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global anti-vascular growth factor therapeutics market was valued at USD 11.67 Billion in 2020. It is expected to increase at a compound annual rate (CAGR of 0.5%) between 2021 and 2028. Market growth in anti-Vascular Endothelial Growth Factor therapeutics can be attributed to an increased prevalence of ophthalmic conditions such as macular edema and diabetic retinopathy, retinal occlusion, Age-related Macular Degeneration, and retinal vein occlusion. There is also an increase in the number of geriatrics who are at risk for developing this condition. The WHO estimates that AMD affects around 196 million people worldwide, with more than 10.4 million suffering from severe to moderate vision impairment. The market is also growing due to product launches and technological advancements.
AMD is the most common cause of vision loss in Canada. It affected approximately 1.4 million people in 2018. According to the European Union, around 34 million people suffered from AMD in 2017. A major market driver is also the alarmingly rising prevalence of diabetes worldwide. According to the Lancet journal, the annual incidence of diabetic retinalopathy is between 12.7% and 2.2% in 2018.
In addition, due to the increasing geriatric population, eye diseases are expected to rise in the future. WHO estimates that the population of older people has grown to 60 million, compared with 5 million children under 5. The geriatric population will reach around 2 billion by 2050 from 900 million in 2015. Globally, there are 125 million people aged 80 and over.
Market players are shifting their focus to longer-acting, VEGF-based products and treatments for these conditions. Novartis' 2019 launch of brolucizumab has increased the competition between the drugs on the market. The longer-acting VEGF medication Beovu (brolucizumab), was introduced in 2019. It has a 3 month loading dose and is then administered every 8 to 12 week.
The companies are also developing new formulations and delivery systems to increase the use of these therapies. F. Hoffmann La Roche Ltd., for instance, is currently undergoing a clinical trial in phase III. This eye implant is refillable and delivers ranibizumab continuously over a number of months.
Market growth is negatively affected by low rates of screening and diagnosis in developing countries for diabetic retinopathy. Market growth is also impeded by the high risk of intraocular injury in anti-VEGF therapy. Patent cliff is another major issue in the pharmaceutical industry. Major blockbuster drugs account for a large portion of turnovers.
Due to the expiry of the patent for Lucentis in the U.S. and Europe in June 2020, key players are involved in developing biosimilars. CoherusBioSciences, Inc. signed a license-and-development agreement with BioeqIP AG in November 2019 for commercialization of Lucentis biosimilars in the U.S. The company plans to bring the product to the market by 2021. This will increase the cost-effectiveness and make it more accessible to a wider range of patients.
Product Insights
With a revenue share exceeding 67%, the Eylea product category dominated the global market for 2020. It is expected to continue its dominance during the forecast period. Due to the advancements in formulations, and the development advanced drug delivery systems, this product will see significant demand. Bayer AG announced in April 2020 that Eylea injection-prefilled syringes will be available in the EU market. This product is currently valid in all 27 EU member countries.
Because it is easy to administer, this new formulation could increase product adoption among ophthalmologists. Beovuis is expected to experience the fastest CAGR during the forecast period due to its patent exclusivity and geographic expansion. Novartis AG announced in February 2020 that the EC approved Beovu (brolucizumab), an injection to treat WAMD. All 27 EU member countries are eligible for the EC approval. Approval of the product in a new geographical area may increase sales and expand customer base.
Disease Insights
Age-related Macular Degeneration (AMD), which accounted for more than 86% of the total market, was the largest segment. This is due to an increasing disease burden, growing elderly population, and the presence of late-stage product candidate candidates that will be entering the market over the next few years. REGENXBIO Inc. is currently conducting a phase II clinical study on its pipeline candidate, RGX-314. It should be ready for commercialization by the end 2023.
Due to the unmet medical need and increasing numbers of diabetic retinopathy treatment approvals, the segment of diabetic-retinopathy is expected to grow at a fastest CAGR over the next few years. Globally, 56% of cases of visual impairment are caused by retinopathy. One-fifth the population of diabetics is affected. Regeneron Pharmaceuticals was approved by the FDA in May 2019 to treat all stages of diabetic retinalopathy. This approval could help fuel growth.
Regional Insights
The North America region had the largest revenue share, more than 64%, in the global market for 2020. Over the forecast period, the regional market will experience a significant increase in sales. The regional market is expected to grow due to factors such as rising disease prevalence, consumer awareness, proactive government actions, technological advances, and improvements in healthcare infrastructure. Market growth will be supported by the presence of major players in North America. F. Hoffmann-La Roche Ltd. has announced the top line clinical trials results of formulation advancement for ranibizumab using Port Delivery System.
These delivery systems, which include technological advances and product launches, are expected to have a positive impact on the market growth. Asia Pacific will grow at a 2.4% CAGR between 2021 and 2028. The key factors driving regional market growth are rising disposable income, increased anti-VEGF product penetration, and increasing consumer awareness. The government may also be taking more initiatives to increase product adoption.
Market Share Insights & Key Companies
Companies are creating strategies that enable them to make use of their resources to help develop new products. F. Hoffmann-La Roche Ltd., for instance, announced positive top-line results from the global phase III study evaluating faricimab among people with DME in December 2020. Faricimab was tolerated well with no safety warnings. The following are some of the major players in the global anti VEGF therapeutics market:
-
F. Hoffmann-La Roche Ltd.
-
Biogen
-
Pfizer, Inc.
-
CoherusBioSciences
-
Amgen, Inc.
-
Bausch Health Companies, Inc.
-
Viatris, Inc.
Up Market Research published a new report titled “Anti-Vascular Endothelial Growth Factor Therapeutics Market research report which is segmented by Disease (AMD, Diabetic Retinopathy), by Product (Beovu, Eylea), By Players/Companies CoherusBioSciences, Viatris Inc, Pfizer Inc, Biogen, Bausch Health Companies Inc, F Hoffmann-La Roche Ltd, Amgen Inc”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Anti-Vascular Endothelial Growth Factor Therapeutics Market Research Report |
| By Disease | AMD, Diabetic Retinopathy |
| By Product | Beovu, Eylea |
| By Companies | CoherusBioSciences, Viatris Inc, Pfizer Inc, Biogen, Bausch Health Companies Inc, F Hoffmann-La Roche Ltd, Amgen Inc |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 215 |
| Number of Tables & Figures | 151 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Report Segments:
The market is segmented by Disease (AMD, Diabetic Retinopathy), by Product (Beovu, Eylea).
Anti-Vascular Endothelial Growth Factor Therapeutics Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Anti-Vascular Endothelial Growth Factor Therapeutics Market
Overview of the regional outlook of the Anti-Vascular Endothelial Growth Factor Therapeutics Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Anti-Vascular Endothelial Growth Factor Therapeutics Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. AMD
2. Diabetic Retinopathy
7. By Product:1. Beovu
2. Eylea
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anti-Vascular Endothelial Growth Factor Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Vascular Endothelial Growth Factor Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Vascular Endothelial Growth Factor Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size and Y-o-Y Growth
4.5.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Disease
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Disease
5.1.2 Basis Point Share (BPS) Analysis by Disease
5.1.3 Absolute $ Opportunity Assessment by Disease
5.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
5.2.1 AMD
5.2.2 Diabetic Retinopathy
5.3 Market Attractiveness Analysis by Disease
Chapter 6 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Product
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product
6.1.2 Basis Point Share (BPS) Analysis by Product
6.1.3 Absolute $ Opportunity Assessment by Product
6.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
6.2.1 Beovu
6.2.2 Eylea
6.3 Market Attractiveness Analysis by Product
Chapter 7 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
9.6.1 AMD
9.6.2 Diabetic Retinopathy
9.7 Basis Point Share (BPS) Analysis by Disease
9.8 Absolute $ Opportunity Assessment by Disease
9.9 Market Attractiveness Analysis by Disease
9.10 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
9.10.1 Beovu
9.10.2 Eylea
9.11 Basis Point Share (BPS) Analysis by Product
9.12 Absolute $ Opportunity Assessment by Product
9.13 Market Attractiveness Analysis by Product
Chapter 10 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
10.6.1 AMD
10.6.2 Diabetic Retinopathy
10.7 Basis Point Share (BPS) Analysis by Disease
10.8 Absolute $ Opportunity Assessment by Disease
10.9 Market Attractiveness Analysis by Disease
10.10 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
10.10.1 Beovu
10.10.2 Eylea
10.11 Basis Point Share (BPS) Analysis by Product
10.12 Absolute $ Opportunity Assessment by Product
10.13 Market Attractiveness Analysis by Product
Chapter 11 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
11.6.1 AMD
11.6.2 Diabetic Retinopathy
11.7 Basis Point Share (BPS) Analysis by Disease
11.8 Absolute $ Opportunity Assessment by Disease
11.9 Market Attractiveness Analysis by Disease
11.10 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
11.10.1 Beovu
11.10.2 Eylea
11.11 Basis Point Share (BPS) Analysis by Product
11.12 Absolute $ Opportunity Assessment by Product
11.13 Market Attractiveness Analysis by Product
Chapter 12 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
12.6.1 AMD
12.6.2 Diabetic Retinopathy
12.7 Basis Point Share (BPS) Analysis by Disease
12.8 Absolute $ Opportunity Assessment by Disease
12.9 Market Attractiveness Analysis by Disease
12.10 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
12.10.1 Beovu
12.10.2 Eylea
12.11 Basis Point Share (BPS) Analysis by Product
12.12 Absolute $ Opportunity Assessment by Product
12.13 Market Attractiveness Analysis by Product
Chapter 13 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
13.6.1 AMD
13.6.2 Diabetic Retinopathy
13.7 Basis Point Share (BPS) Analysis by Disease
13.8 Absolute $ Opportunity Assessment by Disease
13.9 Market Attractiveness Analysis by Disease
13.10 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
13.10.1 Beovu
13.10.2 Eylea
13.11 Basis Point Share (BPS) Analysis by Product
13.12 Absolute $ Opportunity Assessment by Product
13.13 Market Attractiveness Analysis by Product
Chapter 14 Competition Landscape
14.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market: Competitive Dashboard
14.2 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CoherusBioSciences
14.3.2 Viatris Inc
14.3.3 Pfizer Inc
14.3.4 Biogen
14.3.5 Bausch Health Companies Inc
14.3.6 F Hoffmann-La Roche Ltd
14.3.7 Amgen Inc
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anti-Vascular Endothelial Growth Factor Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anti-Vascular Endothelial Growth Factor Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anti-Vascular Endothelial Growth Factor Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size and Y-o-Y Growth
4.5.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Disease
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Disease
5.1.2 Basis Point Share (BPS) Analysis by Disease
5.1.3 Absolute $ Opportunity Assessment by Disease
5.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
5.2.1 AMD
5.2.2 Diabetic Retinopathy
5.3 Market Attractiveness Analysis by Disease
Chapter 6 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Product
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Product
6.1.2 Basis Point Share (BPS) Analysis by Product
6.1.3 Absolute $ Opportunity Assessment by Product
6.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
6.2.1 Beovu
6.2.2 Eylea
6.3 Market Attractiveness Analysis by Product
Chapter 7 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
9.6.1 AMD
9.6.2 Diabetic Retinopathy
9.7 Basis Point Share (BPS) Analysis by Disease
9.8 Absolute $ Opportunity Assessment by Disease
9.9 Market Attractiveness Analysis by Disease
9.10 North America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
9.10.1 Beovu
9.10.2 Eylea
9.11 Basis Point Share (BPS) Analysis by Product
9.12 Absolute $ Opportunity Assessment by Product
9.13 Market Attractiveness Analysis by Product
Chapter 10 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
10.6.1 AMD
10.6.2 Diabetic Retinopathy
10.7 Basis Point Share (BPS) Analysis by Disease
10.8 Absolute $ Opportunity Assessment by Disease
10.9 Market Attractiveness Analysis by Disease
10.10 Europe Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
10.10.1 Beovu
10.10.2 Eylea
10.11 Basis Point Share (BPS) Analysis by Product
10.12 Absolute $ Opportunity Assessment by Product
10.13 Market Attractiveness Analysis by Product
Chapter 11 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
11.6.1 AMD
11.6.2 Diabetic Retinopathy
11.7 Basis Point Share (BPS) Analysis by Disease
11.8 Absolute $ Opportunity Assessment by Disease
11.9 Market Attractiveness Analysis by Disease
11.10 Asia Pacific Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
11.10.1 Beovu
11.10.2 Eylea
11.11 Basis Point Share (BPS) Analysis by Product
11.12 Absolute $ Opportunity Assessment by Product
11.13 Market Attractiveness Analysis by Product
Chapter 12 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
12.6.1 AMD
12.6.2 Diabetic Retinopathy
12.7 Basis Point Share (BPS) Analysis by Disease
12.8 Absolute $ Opportunity Assessment by Disease
12.9 Market Attractiveness Analysis by Disease
12.10 Latin America Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
12.10.1 Beovu
12.10.2 Eylea
12.11 Basis Point Share (BPS) Analysis by Product
12.12 Absolute $ Opportunity Assessment by Product
12.13 Market Attractiveness Analysis by Product
Chapter 13 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Disease
13.6.1 AMD
13.6.2 Diabetic Retinopathy
13.7 Basis Point Share (BPS) Analysis by Disease
13.8 Absolute $ Opportunity Assessment by Disease
13.9 Market Attractiveness Analysis by Disease
13.10 Middle East & Africa (MEA) Anti-Vascular Endothelial Growth Factor Therapeutics Market Size Forecast by Product
13.10.1 Beovu
13.10.2 Eylea
13.11 Basis Point Share (BPS) Analysis by Product
13.12 Absolute $ Opportunity Assessment by Product
13.13 Market Attractiveness Analysis by Product
Chapter 14 Competition Landscape
14.1 Anti-Vascular Endothelial Growth Factor Therapeutics Market: Competitive Dashboard
14.2 Global Anti-Vascular Endothelial Growth Factor Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CoherusBioSciences
14.3.2 Viatris Inc
14.3.3 Pfizer Inc
14.3.4 Biogen
14.3.5 Bausch Health Companies Inc
14.3.6 F Hoffmann-La Roche Ltd
14.3.7 Amgen Inc
Segments Covered in the Report
The global Anti-Vascular Endothelial Growth Factor Therapeutics market has been segmented based on
By Disease
The global Anti-Vascular Endothelial Growth Factor Therapeutics market has been segmented based on
By Disease
- AMD
- Diabetic Retinopathy
- Beovu
- Eylea
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- CoherusBioSciences
- Viatris Inc
- Pfizer Inc
- Biogen
- Bausch Health Companies Inc
- F Hoffmann-La Roche Ltd
- Amgen Inc
Our Clients
Related Reports
Some other reports from this category!
